vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Clear Channel Outdoor Holdings, Inc. (CCO). Click either name above to swap in a different company.
Clear Channel Outdoor Holdings, Inc. is the larger business by last-quarter revenue ($461.5M vs $247.1M, roughly 1.9× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 1.7%, a 9.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 8.2%). Clear Channel Outdoor Holdings, Inc. produced more free cash flow last quarter ($30.3M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 18.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Clear Channel Outdoor Holdings, Inc. is a multinational corporation focused on outdoor advertising. The company is based in San Antonio, Texas.
ANIP vs CCO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $461.5M |
| Net Profit | $27.5M | $8.0M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 23.3% |
| Net Margin | 11.1% | 1.7% |
| Revenue YoY | 29.6% | 8.2% |
| Net Profit YoY | 367.5% | 144.8% |
| EPS (diluted) | $1.14 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $461.5M | ||
| Q3 25 | $227.8M | $405.6M | ||
| Q2 25 | $211.4M | $402.8M | ||
| Q1 25 | $197.1M | $334.2M | ||
| Q4 24 | $190.6M | $426.7M | ||
| Q3 24 | $148.3M | $375.2M | ||
| Q2 24 | $138.0M | $376.5M | ||
| Q1 24 | $137.4M | $326.8M |
| Q4 25 | $27.5M | $8.0M | ||
| Q3 25 | $26.6M | $-60.1M | ||
| Q2 25 | $8.5M | $9.5M | ||
| Q1 25 | $15.7M | $62.5M | ||
| Q4 24 | $-10.3M | $-17.9M | ||
| Q3 24 | $-24.2M | $-32.5M | ||
| Q2 24 | $-2.3M | $-39.2M | ||
| Q1 24 | $18.2M | $-89.7M |
| Q4 25 | 14.1% | 23.3% | ||
| Q3 25 | 15.9% | 19.9% | ||
| Q2 25 | 6.6% | 19.2% | ||
| Q1 25 | 13.3% | 13.5% | ||
| Q4 24 | -2.3% | 23.5% | ||
| Q3 24 | -13.8% | 17.8% | ||
| Q2 24 | 3.7% | 18.2% | ||
| Q1 24 | 14.8% | 13.4% |
| Q4 25 | 11.1% | 1.7% | ||
| Q3 25 | 11.7% | -14.8% | ||
| Q2 25 | 4.0% | 2.4% | ||
| Q1 25 | 8.0% | 18.7% | ||
| Q4 24 | -5.4% | -4.2% | ||
| Q3 24 | -16.3% | -8.7% | ||
| Q2 24 | -1.7% | -10.4% | ||
| Q1 24 | 13.2% | -27.4% |
| Q4 25 | $1.14 | $0.01 | ||
| Q3 25 | $1.13 | $-0.12 | ||
| Q2 25 | $0.36 | $0.02 | ||
| Q1 25 | $0.69 | $0.13 | ||
| Q4 24 | $-0.45 | $-0.03 | ||
| Q3 24 | $-1.27 | $-0.07 | ||
| Q2 24 | $-0.14 | $-0.08 | ||
| Q1 24 | $0.82 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $190.0M |
| Total DebtLower is stronger | — | $5.1B |
| Stockholders' EquityBook value | $540.7M | $-3.4B |
| Total Assets | $1.4B | $3.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $190.0M | ||
| Q3 25 | $262.6M | $155.0M | ||
| Q2 25 | $217.8M | $138.6M | ||
| Q1 25 | $149.8M | $395.8M | ||
| Q4 24 | $144.9M | $109.7M | ||
| Q3 24 | $145.0M | $201.1M | ||
| Q2 24 | $240.1M | $189.3M | ||
| Q1 24 | $228.6M | $193.2M |
| Q4 25 | — | $5.1B | ||
| Q3 25 | — | $5.1B | ||
| Q2 25 | — | $5.1B | ||
| Q1 25 | — | $5.3B | ||
| Q4 24 | — | $5.7B | ||
| Q3 24 | — | $5.7B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $5.7B |
| Q4 25 | $540.7M | $-3.4B | ||
| Q3 25 | $505.8M | $-3.5B | ||
| Q2 25 | $436.8M | $-3.4B | ||
| Q1 25 | $418.6M | $-3.4B | ||
| Q4 24 | $403.7M | $-3.6B | ||
| Q3 24 | $405.9M | $-3.6B | ||
| Q2 24 | $455.8M | $-3.6B | ||
| Q1 24 | $452.0M | $-3.5B |
| Q4 25 | $1.4B | $3.8B | ||
| Q3 25 | $1.4B | $3.8B | ||
| Q2 25 | $1.3B | $3.8B | ||
| Q1 25 | $1.3B | $4.0B | ||
| Q4 24 | $1.3B | $4.8B | ||
| Q3 24 | $1.3B | $4.6B | ||
| Q2 24 | $920.8M | $4.5B | ||
| Q1 24 | $914.5M | $4.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $56.3M |
| Free Cash FlowOCF − Capex | $29.1M | $30.3M |
| FCF MarginFCF / Revenue | 11.8% | 6.6% |
| Capex IntensityCapex / Revenue | 0.5% | 5.6% |
| Cash ConversionOCF / Net Profit | 1.10× | 7.04× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $32.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $56.3M | ||
| Q3 25 | $44.1M | $56.2M | ||
| Q2 25 | $75.8M | $-12.6M | ||
| Q1 25 | $35.0M | $14.9M | ||
| Q4 24 | $15.9M | $29.3M | ||
| Q3 24 | $12.5M | $54.5M | ||
| Q2 24 | $17.4M | $30.8M | ||
| Q1 24 | $18.3M | $-34.8M |
| Q4 25 | $29.1M | $30.3M | ||
| Q3 25 | $38.0M | $41.4M | ||
| Q2 25 | $71.8M | $-29.2M | ||
| Q1 25 | $32.5M | $-10.6M | ||
| Q4 24 | $13.5M | $-27.8M | ||
| Q3 24 | $7.7M | $21.0M | ||
| Q2 24 | $13.0M | $5.2M | ||
| Q1 24 | $13.7M | $-61.0M |
| Q4 25 | 11.8% | 6.6% | ||
| Q3 25 | 16.7% | 10.2% | ||
| Q2 25 | 34.0% | -7.2% | ||
| Q1 25 | 16.5% | -3.2% | ||
| Q4 24 | 7.1% | -6.5% | ||
| Q3 24 | 5.2% | 5.6% | ||
| Q2 24 | 9.4% | 1.4% | ||
| Q1 24 | 10.0% | -18.7% |
| Q4 25 | 0.5% | 5.6% | ||
| Q3 25 | 2.7% | 3.7% | ||
| Q2 25 | 1.9% | 4.1% | ||
| Q1 25 | 1.3% | 7.6% | ||
| Q4 24 | 1.3% | 13.4% | ||
| Q3 24 | 3.2% | 8.9% | ||
| Q2 24 | 3.2% | 6.8% | ||
| Q1 24 | 3.3% | 8.0% |
| Q4 25 | 1.10× | 7.04× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | -1.32× | ||
| Q1 25 | 2.23× | 0.24× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CCO
Segment breakdown not available.
